A scientist uses a multichannel pipette to research cells, genetics and DNA

CREDIT: iStock.com/JVisentin

Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout

Bio-Rad Laboratories, Inc has launched four new Droplet Digital PCR platforms.
| 2 min read
Written byBio-Rad Laboratories
Register for free to listen to this article
Listen with Speechify
0:00
2:00

HERCULES, Calif. — July 7, 2025 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR system along with the QX700™ series of ddPCR platforms acquired as part of the company’s recently completed acquisition of digital PCR developer Stilla Technologies.

Together with Bio-Rad’s existing line of QX200™ and QX600™ ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science research and diagnostic applications. The end-to-end solutions feature industry-leading absolute quantification, high precision, and advanced multiplexing capabilities, combined with streamlined and simplified workflows.

“With this launch, our expanded portfolio of instruments, reagents, software, and services extends Bio-Rad’s presence in the genomics research and applied science markets and strengthens our leadership in droplet digital PCR solutions,” said Jim Barry, EVP and President of Bio-Rad’s Life Science Group. “The newly introduced platforms complement Bio-Rad's existing QX ddPCR portfolio and offer our customers unparalleled workflow simplicity and throughput capabilities across the full spectrum of digital PCR applications including oncology, infectious disease, and genetic research.”

The QX Continuum™ ddPCR system is designed for translational research applications. It features qPCR-like workflow offering simplicity, performance and flexibility in an all-in-one configuration with four-color multiplexing and up to eight discrete thermal profiles per plate.

The QX700™ series consists of three new ddPCR instruments designed for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows. The systems enable seven-color multiplexing, capacity to process over 700 samples per day, with minimal input volume, continuous loading capability, and easy-to-use software for streamlined data interpretation.

To learn more about the new QX Continuum and QX700 series, as well as Bio-Rad’s comprehensive portfolio of digital PCR instruments, consumables, and assays visit: https://www.bio-rad.com/dropletdigitalPCR

BIO-RAD, QX CONTINUUM, QX700, QX600, QX200, DROPLET DIGITAL, and DDPCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A network of interconnected human icons overlaid on a world map, representing global collaboration and population-scale data connections.
New collaborative initiatives are bringing pharmaceutical R&D together around large-scale datasets to accelerate therapeutic discovery.
Modeling neurotropic viral infections using human cerebral organoids
Using fetal-stage brain organoids, researchers are uncovering how Zika virus impacts neurodevelopment and contributes to microcephaly. 
Completing the real-time data picture in bioprocess development
Explore approaches to integrating timely protein titer measurements with cell health data to improve bioprocess visibility and decision-making.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue